The following analyses examine the exposure–response relationships for alectinib in the crizotinib-resistant ALK-positive NSCLC population based on final pooled efficacy and safety data from the pivotal phase II North American study (NP28761; NCT01871805) and the phase II global study (NP28673; NCT01801111) to assess alectinib dose selection in this setting. The gene discussed is ALK; the disease is non-small cell lung carcinoma.